© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2013
Click Here for More Conferences
Click Here for EASL.eu
An Introduction to Hepatitis

Victrelis, Incivek Yield Low Hep C Cures Among Cirrhosis

Victrelis or Incivek-based triple therapy for hepatitis C virus resulted in low cure rates and high rates of serious side effects among those...

Post-Liver Transplant Hep C Responds to Triple Therapy

Treating hepatitis C post-liver transplant yields moderately good results with Victrelis (boceprevir) or Incivek (telaprevir)-based triple the...

Faldaprevir Cures 80% of Hep C in First-time Treatment

Faldaprevir with pegylated interferon and ribavirin cured about 80 percent of treatment-naive people with genotype 1 of hepatitis C in a Phase...

Combo of 2 HIV Drugs Can Control Hep B

The HIV antiretrovirals Viread (tenofovir) and Emtriva (emtricitabine), can suppress hepatitis B in three-quarters of those with ?immune-toler...

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics

Sofosbuvir and Ribavirin Cure 90% of Most Types of Hep C

A Phase III trial sofosbuvir and ribavirin cured 90 percent of those with genotypes 1, 4, 5 and 6 of hepatitis C.

Sofosbuvir, Daclatasvir Combo Cures 100% in Hep C Trial

Sofosbuvir and daclatasvir, taken with or without ribavirin, cured 100 percent of previously treated participants of hepatitis C virus in...

Sofosbuvir and Ribavirin Can Cure Hep C Genotypes 2 and 3

Sofosbuvir and ribavirin cured participants with genotype 2 or 3 of hepatitis C virus at rates in the mid-70 percent range in two new Phase II...

Hot topics

Forums: Support and discussion
Blogs: The community speaks

More Good News From AbbVie’s Five-Drug Hep C Combo

AbbVie?s five-drug hepatitis C virus (HCV) combination therapy demonstrated cure rates in the mid-90 percent range when taken for as little as...

Bristol-Myers Squibb Combo Boasts High Cure Rates for Hepatitis C

Hepatitis C therapy including daclatasvir, asunaprevir and BMS-791325 achieved a cure in up to 94 percent of treatment-naive people with genot...

Simeprevir Cures 80% of Hep C Participants in Phase III Studies

The investigational NS3/4A protease inhibitor simeprevir cured four out of five people with genotype 1 of hepatitis C and compensated liver di...
Advertisement
Science News
Newsfeed
Features
Ask Hep